Skip to main content
ArticleOPEN ACCESS

The evolving clinical profile of abatacept (CTLA4-lg): A novel co-stimulatory modulator for the treatment of rheumatoid arthritis

Arthritis Research and Therapy
DOI: 10.1186/ar1688
91Citations
Citations of this article
55Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Abatacept (CTLA4-Ig) is a novel fusion protein designed to modulate the T cell co-stimulatory signal mediated through the CD28-CD80/86 pathway. Clinical trials have provided preliminary evidence of the efficacy of this compound in the treatment of rheumatoid arthritis. This review describes the molecular and biologic bases for the use of abatacept in rheumatoid arthritis and summarizes the current clinical data on its safety and effectiveness in this disease. © 2005 BioMed Central Ltd.

Cite

CITATION STYLE

APA

Ruderman, E. M., & Pope, R. M. (2005, March). The evolving clinical profile of abatacept (CTLA4-lg): A novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Research and Therapy. https://doi.org/10.1186/ar1688

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free